Polycythemia vera (PV) can qualify for Social Security disability benefits, but it doesn’t have its own standalone listing that guarantees approval. Instead, the Social Security Administration evaluates PV based on the complications it causes and how those complications affect your ability to work. This means the path to approval depends less on the diagnosis itself and more on what the disease has done to your body.
How the SSA Evaluates Polycythemia Vera
The SSA used to have a specific listing for polycythemia vera under Section 7.09 of its Blue Book, which covers hematological disorders. That listing recognized PV when it presented with an excess of red blood cells, an enlarged spleen, and elevated white blood cell or platelet counts. However, the current evaluation approach directs reviewers to assess PV under the body systems it affects rather than as a blood disorder on its own.
In practice, this means the SSA evaluates polycythemia vera under three possible categories: respiratory disorders (Section 3.00), cardiovascular disorders (Section 4.00), or neurological disorders (Section 11.00). The category that applies depends on your specific complications. If PV has caused a stroke, it would be evaluated under the neurological listings. If it has led to blood clots in your lungs, the respiratory listings apply. Heart damage from clotting events falls under cardiovascular criteria.
Qualifying Through Complications
The most direct route to approval is through serious, documented complications. The SSA’s listing for disorders of thrombosis and hemostasis (7.08) covers conditions involving abnormal blood clotting, which is one of the primary dangers of PV. To meet this listing, you need complications that required at least three hospitalizations within a 12-month period, with each hospitalization at least 30 days apart from the others. Each hospital stay must have lasted at least 48 hours, including time spent in the emergency department immediately before admission. Qualifying complications include blood clots, embolisms, and uncontrolled bleeding.
If PV progresses to myelofibrosis, a condition where scar tissue replaces bone marrow, the SSA evaluates it under listing 7.10 for bone marrow failure disorders. This listing also requires three hospitalizations within 12 months under the same rules described above.
When PV transforms into acute leukemia, which happens in a small percentage of cases, it gets evaluated under the cancer listings, which generally have more straightforward approval criteria.
The Catch-All Listing for Repeated Complications
Many people with PV don’t meet the strict hospitalization thresholds but still experience complications that make working impossible. Listing 7.18 exists for exactly this situation. It covers repeated complications of hematological disorders that don’t fully meet the requirements of other listings but still cause significant, documented symptoms.
Under 7.18, the SSA considers a wide range of symptoms and complications: pain, severe fatigue, malaise, fever, night sweats, headaches, joint or muscle swelling, shortness of breath, skin ulcers, vision problems, and cognitive or mental limitations. To qualify, these symptoms must result in a “marked” limitation in at least one key area of functioning, such as your ability to perform daily activities, maintain social functioning, or complete tasks in a timely manner.
This listing is particularly relevant for PV patients because the disease’s day-to-day symptom burden can be severe even without dramatic hospitalization events.
How PV Symptoms Affect Work Capacity
A large survey of patients living with myeloproliferative neoplasms, the category of blood cancers that includes PV, found that the symptom burden significantly impairs both work productivity and daily activities. Fatigue, concentration problems, and inactivity showed the strongest correlation with work impairment. Among PV patients specifically, 55% reported persistent itching and 45% experienced night sweats, both of which can disrupt sleep and focus.
Concentration problems deserve special attention in disability claims. If you struggle to stay focused, process information, or complete tasks at a reasonable pace, these cognitive effects can be documented and factored into your claim. Fatigue in PV isn’t ordinary tiredness; it’s a deep, persistent exhaustion that doesn’t resolve with rest and can make sustaining an eight-hour workday unrealistic.
Even if your symptoms don’t match a specific Blue Book listing, the SSA is required to assess your residual functional capacity, which is essentially a determination of what work you can still do given all of your limitations. This assessment considers physical restrictions, mental limitations, fatigue levels, and how often you need medical appointments like phlebotomy sessions. If the SSA concludes you can’t sustain any type of full-time work, you can be approved for disability even without meeting a specific listing.
Building a Strong Claim
Because PV doesn’t have a simple, automatic path to approval, documentation is everything. Your medical records should clearly show the frequency and severity of your symptoms, any complications like blood clots or strokes, how often you need treatment, and how the disease limits your daily functioning. Detailed notes from your hematologist about fatigue levels, cognitive difficulties, and physical limitations carry significant weight.
Keep a record of how your symptoms affect your ability to work. If you’ve had to reduce your hours, miss days due to fatigue or medical appointments, or leave a job entirely, that history matters. The SSA looks at the full picture: your diagnosis, your complications, your treatment burden, and the gap between what your job requires and what your body can reliably do.
Initial disability claims are denied at high rates across all conditions, and PV claims can be particularly challenging because the disease varies so much from person to person. Someone with well-controlled PV managed by occasional phlebotomy may have trouble proving disability, while someone dealing with recurrent clotting events, debilitating fatigue, or progression to myelofibrosis has a much stronger case. If your initial application is denied, you have the right to appeal, and approval rates improve significantly at the hearing level where you can present your case in more detail.